Abstract:Dear Editor, Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma (NHL), accounting for about 40% of all NHL cases [1]. Lacking symptoms at early time and efficient therapeutic methods made DLBCL one of the most life-threatening types of hematopoietic malignancy [2, 3]. Therefore, identifying novel therapeutic biomarker for early detection and prognosis prediction is urgently needed. Thanks to large-scale gene expression profiling between DLBCL and normal B cells, vast groups of genes have been found deregulated. Moreover, various long non-coding RNAs (lncRNAs) have been reported aberrantly expressed in DLBCL [4, 5]. Previous studies showed that lncRNA plasmacytoma variant translocation 1 (PVT1) is an important epigenetic regulator with critical roles in human tumors [6]. Indeed, by searching the online database (starBase pan-cancer project database, version 3.0; http://starbase.sysu.edu.cn/), we found that PVT1 was elevated in most kinds of tumors (Supplementary Figure S1A). However, the overall biological role and clinical significance of PVT1 in DLBCL remains largely unknown. In order to determine the possible involvement of PVT1 in DLBCL, we retrieved 286 formalin-fixed, paraffin-embedded (FFPE) DLBCL tissues and 62 normal lymph node FFPE tissues from DLBCL patients treated at Renji hospital (Shanghai, China) between January 1st, 2012 and December 31st, 2017. Furthermore, we also collected 46 paired fresh DLBCL tissues and normal lymph node tissues. The clinical information of the enrolled DLBCL patients was recapitulated in Supplementary Table S1. The materials and methods used in this study were detailed in Supplementary information. We firstly assessed PVT1 expression via real-time PCR (RT-PCR) in 46 paired fresh DLBCL tissues and normal lymph node tissues. The expression of PVT1 was found to be significantly increased in DLBCL tissues as compared to their normal counterparts (P < 0.001; Supplementary Figure S1B). PVT1 upregulation in tumor tissues was detected in 39 (84.8%) patients with DLBCL (Supplementary Figure S1C). Furthermore, in situ hybridization (ISH) staining on 286 DLBCL and 62 normal lymph node FFPE tissues confirmed that PVT1 expression was remarkably increased in DLBCL FFPE tissues (P < 0.001; Supplementary Figure S1D). These results suggested that the PVT1 was significantly upregulated in DLBCL tissues. In order to explore the clinical significance of PVT1 in DLBCL patients, we then analyzed the correlation between PVT1 expression and clinicopathological features in DLBCL patients. We found that the expression of PVT1 was positively correlated with the expression of myelocytomatosis oncogene (MYC) in 46 fresh DLBCL tissues (P < 0.001; Supplementary Figure S2A). Additionally, the ISH score of PVT1 was positively correlated with tumor size and Ki67+ cell rate in those 286 DLBCL (both P < 0.001; Supplementary Figure S2B and C). Both univariate (Chi-squared test) and multivariate (Logistic regression) analyses confirmed that high PVT1 expression was associated with multiple extranodal site involvement (ESI) in DLBCL patients (P = 0.007; Supplementary Table S1). DLBCL patients were then divided into low and high PVT1 expression groups according to the ISH score for survival analysis (Supplementary Figure S2D). Kaplan-Meier analysis was performed to assess the prognostic significance of PVT1 expression in 286 DLBCL patients. The results showed that patients with low PVT1 expression had increased progression-free survival (PFS; hazard ratio [HR] = 2.10; 95% confidence interval [CI] = 1.42-3.12; P < 0.001) and overall survival (OS) rate (HR = 2.29; 95% CI = 1.45-3.62; P < 0.001; Figure 1A). The 5-year PFS and OS rates of high and low PVT1 expression groups were 51.0% vs. 72.8% and 61.4% vs. 82.5%, respectively. Multivariate Cox proportional hazards model showed that high PVT1 expression was associated with reduced PFS (relative risk [RR] = 1.85; 95% CI = 1.19-2.89; P = 0.006) and OS rates (RR = 1.91, 95% CI = 1.13-3.23; P = 0.015; Supplementary Table S2). Moreover, we analyzed the PFS and OS by combine PVT1 expression and national comprehensive cancer network international prognostic index (NCCN IPI) to assess the prognosis prediction ability. We found that this combination could further divide the DLBCL patients into four groups, with the group of both low PVT1 expression and low NCCN IPI possess the best PFS and OS while both high PVT1 expression and high NCCN IPI group possess the worst (Figure 1B). Taken together, our results provide evidence showing the potential of PVT1 as an important prognostic factor for DLBCL patients. PVT1 is a prognostic factor for DLBCL patients and plays an important oncogenic role in DLBCL in vitro and in vivo. A. Kaplan-Meier analysis of the correlation between PVT1 expression and the PFS (left panel) or OS (right panel) in 286 DLBCL patients. B. The significance of combination of PVT1 expression and NCCN IPI score in DLBCL survival (PFS and OS). C. Cell proliferation analysis of DB cells transiently transfected with PVT1 siRNA (si-PVT1#1 and si-PVT1#2). DB cells transfected with control siRNA (si-Con) were served as control. D. Cell proliferation analysis of DB cells transiently transfected with PVT1overexpression plasmids (PVT1). DB cells transfected with empty vector (Vector) served as control. E. Cell cycle distributions of DB cells transfected with PVT1 siRNA (si-PVT1#1 and si-PVT1#2). The cell cycle distributions were assessed by measuring DNA content of PI-stained cells using flow cytometry. DB cells transfected with control siRNA (si-Con) were served as control. F. Tumor growth curves of DB cells transfected with PVT1 shRNA in vivo. DB cells transfected with control shRNA (sh-Con) were served as control. G. Representative images of mice at the 6th week after separately subcutaneous transplantation of DB cells transfected with PVT1 shRNA. The mice transplanted with DB cells treated with control shRNA (sh-Con) were served as control. H. The mean tumor weight of mice received DB cells with or without PVT1 knockdown. I. The tumor-free percentages of mice received DB cells with or without PVT1 knockdown. Bar, SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Abbreviations: PVT1, plasmacytoma variant translocation 1; DLBCL, diffuse large B-cell lymphoma; SEM, standard error of mean; PFS, progression-free survival; OS, overall survival; shRNA, short hairpin RNA; siRNA, small interfering RNA; PI, propidium iodide For further exploring the biological role of PVT1 in DLBCL, we carried out both in vitro and in vivo analysis. Reducing PVT1 expression by two small interfering RNAs (siRNAs) in four DLBCL cell lines (DB, OCI-Ly10, BJAB, and OCI-Ly1) all significantly reduced their proliferation rates (Figure 1C and Supplementary Figure S3A). Contrarily, elevating PVT1 expression by transfecting PVT1 overexpression plasmid promoted DLBCL cells proliferation (Figure 1D and Supplementary Figure S3B). Further cell cycle analysis showed that reduced PVT1 expression in DB and OCI-Ly1 induced G0/G1 arrest (Figure 1E and Supplementary Figure S3C). Finally, reducing PVT1 expression by short hairpin RNA (shRNA) in both DB and OCI-Ly1 impeded tumor growth on mouse xenograft models, as shown by reduced tumor volume, tumor weight, and tumor formation rate (Figure 1F–I and Supplementary Figure S4). Taken together, these results indicate that PVT1 influenced DLBCL cells’ proliferation capacity, possibly through regulating cell cycle progression. Although the current standard treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has improved the outcome of DLBCL patients remarkably, there still existed over 30% of patients encounter relapse or refractory [2]. Recent years, the high throughput sequencing technologies have helped define the molecular and biological events with DLBCL development comprehensively [4]. Cumulative evidences suggested the importance of lncRNA in cancer development and progression [5-8]. A recent study into analyzing the lncRNA expression profile of DLBCL patients has suggested a six-lncRNA signature could efficiently predict the outcome of DLBCL patients [4]. Therefore, it is meaningful to find novel lncRNAs for pre-assessment of DLBCL patients’ prognosis. In the present study, we provided evidences that elevated PVT1 expression was found in DLBCL tissues compared with normal lymph node tissues, and was positively associated with adverse clinicopathological outcomes. Moreover, the PVT1 expression was also a potent independent poor prognostic factor in DLBCL. Consistently, genome-wide association study confirmed the association between PVT1 variants with DLBCL development [9]. PVT1 has been studied in a variety of pathological processes about tumorigenesis and tumor progression. However, the role of PVT1 played in DLBCL remained to be clarified. Similarly, our results showed that silencing PVT1 expression significantly inhibit DLBCL cell proliferation both in vitro and in vivo. Opposite effect was observed with PVT1 overexpression. Uncontrolled cell proliferation is the hallmark of cancer cells, most of which are fulfilled through directly regulating cell cycle progression [10]. Our flow cytometric results indicated that reducing PVT1 in DB and OCI-Ly1 cells induced G1 phase arrest and suppressed cell proliferation. However, similar effects were not observed among OCI-Ly10 and BJAB cells, suggesting other mechanisms might be used by PVT1 in regulating DLBCL tumorigenesis. In conclusion, our investigations first elucidated the dysregulation of PVT1 expression in DLBCL, and determined the prognostic value of PVT1 for DLBCL patients. Furthermore, we confirmed the oncogenic role of PVT1 in DLBCL development both in vitro and in vivo. These would possibly provide rationale for future targeting PVT1 in DLBCL. The protocol of this study was approved by the Shanghai Ninth People's Hospital and Renji Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University. The need for informed consent was waived. Not applicable. The datasets are available from the corresponding authors on reasonable request. The authors declare that they have no competing interests. MZ and LY designed and conducted the study. RY, TS, ML, and YS collected clinical samples and data. RY, ML, YS and QL performed the experiments. MZ and LY wrote the manuscript and prepared the figures and tables. All authors reviewed and approved the final manuscript. Not applicable. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:To the Editor: Esophageal squamous cell carcinoma (ESCC) is the seventh most common malignant cancer worldwide.[1] There is an urgent need to find sensitive and specific biomarkers to improve ESCC diagnosis and prognosis.[2] Tumor-specific long non-coding RNA (lncRNA) seems to be potential biomarkers for the diagnosis and treatment of cancer.[3] Our previous study has performed data mining analyses for ESCC and identification of the dysregulated lncRNAs from the Gene Expression Omnibus database (GEO, https://www.ncbi.nlm.nih.gov/sites/GDSbrowser).[4] The results demonstrated that lncRNA plasmacytoma variant translocation 1 (PVT1) gene expression is significantly up-regulated in ESCC tumor tissues. In the present study, we analyze the feasibility of using PVT1 as a tumor molecular marker and discuss its potential clinical applications. We designed a experiment to investigate the PVT1 expression in ESCC tissues, microarray data, The Cancer Genome Atlas (TCGA) database, and ESCC-related human cell lines. In addition, the relationships between PVT1 expression and clinicopathological parameters and the prognosis of ESCC patients were assessed. The biological function of PVT1 in vitro was assessed using built vectors of silencing lentivirus. Furthermore, bioinformatics and proteins expression analyses were performed to investigate the regulatory mechanism of PVT1. This study was approved by the Ethics Committee of Wuwei Tumor Hospital of Gansu (No. WWZLYY-LL-200603) and compliance with the Declaration of Helsinki. Written informed consent was provided by all patients before the start of the study. A total of 77 patients with ESCC (age 40–75 years) from Wuwei Tumor Hospital of Gansu (China) were recruited between 2019 and 2020 [Supplementary Table 1, https://links.lww.com/CM9/A992]. All patients were diagnosed using the Cancer Staging Manual and had no cancer other than ESCC. Non-cancerous tissues were located ≥5 cm from the tumor edge. Samples were stored in RNAlater (Ambion; Thermo Fisher Scientific, Inc.) at −80°C until subsequent experimentation. Patients’ information was recorded, including sex, age, tumor-node-metastasis (TNM) stage, and pathological type. Statistical analysis was performed using SPSS Statistics 21.0 software (International Business Machines Corporation, Armonk, NY, USA). The paired t test, analysis of variance, Tukey's posthoc test, and x2 test were used to compare differences between groups. Kaplan–Meier survival analysis was performed to assess the association between PVT1 expression and the survival of patients with ESCC. P < 0.05 was considered to indicate a statistically significant difference. Integrated analysis of PVT1 expression was performed using 279 profiles of ESCC tumor tissues and normal esophagus tissues sequencing data from TCGA database [Supplementary Table 2, https://links.lww.com/CM9/A992]. In addition, PVT1 expression levels in 77 pairs of ESCC tumor tissues and their paired adjacent non-cancerous tissues were detected by real-time quantitative PCR (RT-qPCR). Results showed that the PVT1 expression was remarkably up-regulated (10.88 ± 2.41 vs. 13.46 ± 3.29; P < 0.05; Figure 1A). PVT1 expression levels in microarray detection and TCGA database were also remarkably raised in ESCC tumor tissues than non-cancerous esophagus tissues (fold change = 6.82 ± 1.79, 9.81 ± 1.57, and 6.94 ± 0.37; Figure 1B). As shown in Supplementary Table 3, https://links.lww.com/CM9/A992, the increased risk of 77 ESCC patients were linked with PVT1 increased expression (odds ratio [OR], 1.639; P < 0.05) and the TCGA database (OR, 1.327; P < 0.05). In this study, we found that the OR value of PVT1 expression in patients with ESCC and TCGA database were both greater than 1.0, which suggested that PVT1 may play an oncogene role during the ESCC development.Figure 1: (A) PVT1 expression level was significantly up-reguated in ESCC tumor tissues (n = 77), ∗ P < 0.05. (B) The expression of PVT1 in ESCC tumor tissues, microarray data, and TCGA database. (C) RT-qPCR analysis of PVT1 expression in ESCC cell lines EC9706, EC109, and TE-1, and normal esophageal mucosa cell line HEEC. (D) ROC curve of the expression level of PVT1 in ESCC tissues for RT-qPCR (n = 77). (E) ROC curve of the expression level of PVT1 of ESCC tissues from TCGA database RNA sequencing (n = 279). (F) Kaplan–Meier survival analysis of the PVT1 expression and TCGA ESCC patients’ overall survival time correlation. (G) Effect of lentivirus-PVT1-siRNA on EC109 cell lines, Cell proliferation was measured by MTT assay; (H) Effects of lentivirus-PVT1-siRNA on the cell cycle of EC109 cells, ∗ P < 0.05. (I) Effects of lentivirus-PVT1-siRNA on apoptosis of EC109 cells. (J) Typical western blotting bands. (K) Relatively optical density analyzed of proteins expression by Image pro plus software. ESCC: Esophageal squamous cell carcinoma; HEEC: Human esophageal epithelial cell; MTT: Thiazolyl blue tetrazolium bromide; PVT1: Plasmacytoma variant translocation 1 gene; ROC: Receiver operating characteristic; RT-qPCR: Real-time quantitative PCR; siRNA: Small interfering RNA; TCGA: The Cancer Genome Atlas.Receiver operating characteristic (ROC) curve analysis showed that the PVT1 can distinguish ESCC patients’ tumor tissues and non-tumor tissues with high diagnostic power (area under the curve [AUC], 0.753; P<0.05, 95% confidence interval: 0.717–0.839) and the TCGA database (AUC, 0.855, P < 0.05, 95% confidence interval: 0.804–0.906) [Figure 1D and 1E]. Supplementary Table 4, https://links.lww.com/CM9/A992 shows that PVT1 was up-regulated in 77 ESCC tumor tissues and associated with the tumor degree of differentiation and TNM stages of patients with ESCC (P < 0.05). Kaplan–Meier survival analysis demonstrated that patients with high PVT1 expression had a poor prognosis (P < 0.05; Figure 1F). In addition, the PVT1 was up expressed in ESCC cell lines (EC9706, EC109, and TE-1) which compared with normal human esophageal epithelial cell [Figure 1C]. To explore the potential biological function of PVT1 in ESCC progression, EC109 cells were stably transfected with lentivirus-PVT1-small interfering RNA (siRNA) or negative control lentivirus. As presented in Supplementary Figure 1A and 1B, https://links.lww.com/CM9/A992, the transfection efficiency was almost 100% and decreased by 25.07 times in EC109 cells by transfected with lentivirus-PVT1-siRNA (P < 0.05; Supplementary Figure 1C, https://links.lww.com/CM9/A992). The thiazolyl blue tetrazolium bromide assay demonstrated that the proliferative ability of EC109 cells significantly decreased following transfection with lentivirus-PVT1-siRNA than blank and negative controls (P < 0.05; Figure 1G). Cell cycle assay detection results showed that the lentivirus-PVT1-siRNA transfection significantly decreased the number of EC109 cells in the G2/M phase, while increasing the number of cells in the S phase, which compared with the blank and negative control group (P < 0. 05; Figure 1H and Supplementary Figure 1D, https://links.lww.com/CM9/A992). Flow cytometry detection showed that the late cell apoptosis rate and the total cell apoptosis rate were significantly increased in the lentivirus-PVT1-siRNA stable transfection group, which compared with the blank and negative control group (P < 0.05; Figure 1I and Supplementary Figure 1E, https://links.lww.com/CM9/A992). Based on the TCGA database and the competing endogenous RNA theory, we analyzed the PVT1 coexpressed ESCC differentially expressed mRNAs functionally enriched and potentially regulated signaling pathways. We have found that there were 83 Gene Ontology terms and 43 pathways enrichment score more than two times (P < 0.05). Results suggested that the most enriched function of up-regulated mRNAs was “Regulation of cellular response” and “Biological process,” such as “Cell division,” “Biological regulation,” etc. [Supplementary Figure 1F, https://links.lww.com/CM9/A992]. In addition, we found that the predominantly enriched tumor-associated signaling pathways were in “Cancer,” “Wnt signaling pathway,” and “MAPK signaling pathway” [Supplementary Figure 1G, https://links.lww.com/CM9/A992]. Notably, the results of our previous study also revealed that the Wnt signaling pathway is involved in regulating the cancer cell cycle and affecting the process of ESCC. Thus, to further verify whether PVT1 regulates the development of ESCC through the Wnt signaling pathway, western blot was used to analyze the differences in expression levels of the key proteins. Results showed that the protein expression levels of b-catenin and TCF-7 were downregulated in the lentivirus-PVT1-siRNA group, p-GSK-3β/GSK-3β and Axin1 was up-regulated in the lentivirus-PVT1-siRNA group than blank and negative controls (P < 0.05; Figure 1J and 1K). The results demonstrated that the Wnt pathway was inhibited by transfection with lentivirus-PVT1-siRNA. The present study demonstrated that up-regulated PVT1 expression in ESCC tissues was associated with a higher occurrence rate of ESCC, which was similar to other reports concerning PVT1.[5] ROC curve analysis demonstrated that PVT1 may be a valid diagnostic biomarker of ESCC. Cell functional experiments revealed that the lentivirus-PVT1-siRNA transfection inhibits the proliferation of EC109 cells by affecting the process of the cell cycle. In addition, our results also revealed that the PVT1 may affect the function of EC109 cells by regulating and activating the Wnt signaling pathway. To conclude, up-regulated PVT1 can induce the ESCC tumorigenesis through regulating the cell cycle and Wnt signaling pathway. These results provide a novel insight that PVT1 may be prospective biomarkers and therapeutic target for patients with ESCC. Funding This study was financially supported by grants from the Fundamental Research Funds for the Central Universities (No.lzujbky-2020-54) and the National Natural Science Foundation of China (No.81803188). Conflicts of interest None.

Long Noncoding RNA PVT1 Promotes Tumor Growth and Predicts Poor Prognosis in Patients with Diffuse Large B‐cell Lymphoma

LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway

Knockdown of long non-coding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p.

Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer

Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1

Long Non-Coding RNA PVT1 Promotes Tumor Progression by Regulating the Wnt Pathway in Human Esophageal Squamous Cell Carcinoma.

PVT1 promotes proliferation and macrophage immunosuppressive polarization through STAT1 and CX3CL1 regulation in glioblastoma multiforme

Lncrna PVT1 Identified As an Independent Biomarker for Prognosis Surveillance of Solid Tumors Based on Transcriptome Data and Meta-Analysis

Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma

Long Noncoding RNA PVT1 Indicates a Poor Prognosis of Gastric Cancer and Promotes Cell Proliferation Through Epigenetically Regulating P15 and P16

Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia

Long Noncoding RNA PVT1 As a Potent Predictor of Prognosis in Cancers: a Meta-Analysis.

Increased expression of long non-coding RNA PVT 1 correlates with clinical progression and poor prognosis in bladder cancer

Long non-coding RNA PVT1 regulates the proliferationand metastasis of human breast cancer via theWnt/b-catenin signalling pathway

Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases.

Role of long non-coding RNA PVT1 in proliferation of acute promyelocytic leukemia

Upregulation of Long Noncoding RNA PEG10 Associates with Poor Prognosis in Diffuse Large B Cell Lymphoma with Facilitating Tumorigenicity

Prognostic Value of Long Non-Coding RNA PVT1 As a Novel Biomarker in Various Cancers: a Meta-Analysis.

Correction For: LncRNA PVT1 Accelerates Malignant Phenotypes of Bladder Cancer Cells by Modulating Mir-194-5p/bclaf1 Axis As a Cerna

Lncrna PVT1 Promotes Tumorigenesis of Colorectal Cancer by Stabilizing Mir-16-5p and Interacting with the VEGFA/VEGFR1/AKT Axis

Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulation.